R
Regado Biosciences
Develops antithrombotic drug systems for acute and sub-acute cardiovascular and other indications
About Regado Biosciences
Regado Biosciences is at the forefront of developing innovative therapeutic technologies, focusing on creating two-component drug systems. These systems consist of a nuclease-stabilized RNA aptamer and a complementary oligonucleotide active control agent, allowing for precise control over therapeutic effects. The company's primary application is in the field of injectable antithrombotics, including anticoagulants and antiplatelet agents, targeting the acute and sub-acute care market. This market is substantial, valued in the billions, and demands safer and more controllable therapeutic options. Regado's technology aims to provide physicians with the ability to actively manage and personalize treatment, enhancing patient safety and outcomes. The business model revolves around the development and commercialization of these advanced therapeutic systems, generating revenue through partnerships, licensing agreements, and direct sales to healthcare providers.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2001
- Headquarters
- Durham, United States
- Listing
- IPO 2013
- Employees
- 2
- Open positions
- None listed
- Dealroom signal
- 58.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Cardiology and cardiovascular, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B, B2C
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Jan 2014 | $20M | — | Undisclosed | — |
| IPOOther financing | Aug 2013 | $0 | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Regado Biosciences is 0 monthly website visits. Regado Biosciences's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Regado Biosciences in the Durham ecosystem
The Regado Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later7 investors entered at this stage
- CFCaxton Advantage Life Sciences Fund
Domain Associates
Andera Partners
RMI Partners- QPQuaker Partners
Baxter Ventures- RURusnano
Other known investors1 additional known investor
Duke University
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Regado Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Regado Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








